
|Articles|April 4, 2008
GSK revises Relenza prescribing information to warn of abnormal behavior
GlaxoSmithKline updates Warnings and Precautions sections of zanamivir prescribing information
Advertisement
GSK revises Relenza prescribing information to warn of abnormal behaviorPostmarketing reports of delirium and abnormal behavior in patients with influenza who are receiving neuraminidase inhibitors have prompted GlaxoSmithKline to update the prescribing information for zanamivir (
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Heat and Older Adults: What Pharmacists Need to Know
5





























































